DR. STEVEN M FRUCHTMAN, M.D.
Medical Practice in New York, NY
License number
New York 135990
Category
Medical Practice
Type
Specialist
Address
Address
1150 Fw SUITE 1, New York, NY 10128
Phone
(212) 427-7700
(212) 996-8034 (Fax)
(212) 996-8034 (Fax)
Personal information
See more information about STEVEN M FRUCHTMAN at radaris.comName
Address
Phone
471 Cold Spring Rd, Syosset, NY 11791
10 Candy Ln, Great Neck, NY 11023
17 96Th St, New York, NY 10128
5 98Th St, New York, NY 10029
5 98Th St, New York, NY 10029
Professional information
Chief Medical Officer At Spectrum Pharmaceuticals
Position:
Chief Medical Officer at Spectrum Pharmaceuticals
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Spectrum Pharmaceuticals
- Irvine, CA since Jul 2011
-
Chief Medical Officer
Spectrum Pharmaceuticals
- Irvine, CA Feb 2011 - Aug 2011
-
Executive Vice President
Allos Therapeutics
2009 - 2011
-
VP; Clinical Development
Novartis
2007 - 2009
-
Sr Director
Skills:
Clinical Development, Oncology, Pharmaceutical Industry, Clinical Trials, Biotechnology
Writing And Editing Professional
Location:
Greater New York City Area
Industry:
Writing and Editing
Dr. Steven M Fruchtman, New York NY - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
1111 Park Ave, New York 10128
(212) 427-7700 (Phone), (212) 996-8034 (Fax)
(212) 427-7700 (Phone), (212) 996-8034 (Fax)
Certifications:
Hematology, 1984, Internal Medicine, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York Medical College
Graduated: 1977
Kings County Hospital Center
Mount Sinai Hospital
New York Medical College
Graduated: 1977
Kings County Hospital Center
Mount Sinai Hospital
Vp Clinical Development At Allos Therapeutics
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Methods For Extending Progression-Free Survival Using 10-Propargyl-10-Deazaaminopterin
US Patent:
2013017, Jul 11, 2013
Filed:
Aug 5, 2011
Appl. No.:
13/816157
Inventors:
Steven M. Fruchtman - New York NY, US
Assignee:
ALLOS THERAPEUTICS, INC. - Westminster CO
International Classification:
A61K 31/519, A61K 31/7052
US Classification:
514 52, 514249
Abstract:
The present invention includes a method to reverse the trend towards progressive resistance to consecutive treatments for T-cell lymphoma in a patient. This method includes selecting a patient having T-cell lymphoma, wherein the patient has had at least one prior treatment for T-cell lymphoma, wherein the prior treatment comprises non-10-propargyl-10-deazaaminopterin; and administering to the patient a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaminopterin, whereby the trend towards progressive resistance is reversed.